Genotype-phenotype correlation for thiopurine S-methyltransferase in healthy Italian subjects

被引:81
作者
Rossi, AM
Bianchi, M
Guarnieri, C
Barale, R
Pacifici, GM
机构
[1] Sch Med, Pharmacol Sect, Dept Neurosci, I-56126 Pisa, Italy
[2] Dept Human & Environm Sci, Lab Genet & Environm Mutagenesis, I-56126 Pisa, Italy
关键词
thiopurine methyltransferase; erythrocytes; genotyping; phenotyping;
D O I
10.1007/s002280000246
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objective: The aim of the present study was to estimate the concordance rate between erythrocyte thiopurine methyltransferase (TPMT) activity and genotype at the TPMT locus in an Italian population sample. Methods: The TPMT phenotype and genotype were determined in an unrelated population of 103 Italian healthy blood donors. Erythrocyte TPMT activity was measured with a radiochemical assay using 12.5 muM S-adenosyl-L-(methyl-C-14)-methionine and 4 mM 6-mercaptopurine. The genotyping assay was based on restriction fragment length polymorphism polymerase chain reaction (RFLP-PCR) and allele-specific oligonucleotide polymerase chain reaction (ASO-PCR) methods. Results: All subjects had detectable TPMT activity. The activity of TPMT varied 2.8-fold between the 5th and 95th percentile. This variation was neither age (P = 0.63) nor gender (P = 0.44) regulated and the frequency distribution of TPMT activity is compatible with a polymorphic distribution. The presence of the four most common defective alleles, i.e. TPMT*2, TPMT*3A, TPMT*3B and TPMT*3C, was examined through the entire phenotyped population. Ninety-two subjects did not carry any of the tested mutations, Eleven individuals were heterozygous for one of the mutant alleles and had a TPMT activity lower than 30 pmol/min/mg. Eight subjects were TPMT*1/TPMT*3A, two TPMT*1/TPMT*3C and one was TPMT*1/TPMT*2. The TPMT*3B allele was not detected in the samples analysed. Conclusion: There was a concordance of 97% between genotype and phenotype. All the heterozygotes had an intermediate phenotype. However, the wide variation range in TPMT activity detected in the wild-type homozygotes indicates that other genetic or epigenetic factors influence the TPMT phenotype.
引用
收藏
页码:51 / 54
页数:4
相关论文
共 18 条
[1]   Thiopurine biology and pharmacology [J].
Aarbakke, J ;
JankaSchaub, G ;
Elion, GB .
TRENDS IN PHARMACOLOGICAL SCIENCES, 1997, 18 (01) :3-7
[2]   Variability in the rate of 6-mercaptopurine methylation in the erythrocytes, liver and kidney in an Italian population [J].
Ferroni, MA ;
Marchi, G ;
Sansone, E ;
Romeo, P ;
Giulianotti, PC ;
Pietrabissa, A ;
Mosca, F ;
Pacifici, GM .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1996, 51 (01) :23-29
[3]   Genetic polymorphism of thiopurine S-methyltransferase: Clinical importance and molecular mechanisms [J].
Krynetski, EY ;
Tai, HL ;
Yates, CR ;
Fessing, MY ;
Loennechen, T ;
Schuetz, JD ;
Relling, MV ;
Evans, WE .
PHARMACOGENETICS, 1996, 6 (04) :279-290
[4]   Pharmacogenetics as a molecular basis for individualized drug therapy: The thiopurine S-methyltransferase paradigm [J].
Krynetski, EY ;
Evans, WE .
PHARMACEUTICAL RESEARCH, 1999, 16 (03) :342-349
[5]   Clinical implications of thiopurine methyltransferase - Optimization of drug dosage and potential drug interactions [J].
Lennard, L .
THERAPEUTIC DRUG MONITORING, 1998, 20 (05) :527-531
[6]  
Lennard L, 1999, BRIT J CLIN PHARMACO, V47, P131
[7]  
LOWRY OH, 1951, J BIOL CHEM, V193, P265
[8]   Genetic polymorphism of thiopurine methyltransferase and its clinical relevance for childhood acute lymphoblastic leukemia [J].
McLeod, HL ;
Krynetski, EY ;
Relling, MV ;
Evans, WE .
LEUKEMIA, 2000, 14 (04) :567-572
[9]   HIGHER ACTIVITY OF POLYMORPHIC THIOPURINE S-METHYLTRANSFERASE IN ERYTHROCYTES FROM NEONATES COMPARED TO ADULTS [J].
MCLEOD, HL ;
KRYNETSKI, EY ;
WILIMAS, JA ;
EVANS, WE .
PHARMACOGENETICS, 1995, 5 (05) :281-286
[10]   Human thiopurine methyltransferase pharmacogenetics: Gene sequence polymorphisms [J].
Otterness, D ;
Szumlanski, C ;
Lennard, L ;
Klemetsdal, B ;
Aarbakke, J ;
ParkHah, JO ;
Iven, H ;
Schmiegelow, K ;
Branum, E ;
OBrien, J ;
Weinshilboum, R .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1997, 62 (01) :60-73